If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The facility will manufacture tablets, capsules, and injections for the oncology segment
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Subscribe To Our Newsletter & Stay Updated
